1. Allergan's Botox still physician fave for migraine despite CGRP push — Lilly to sponsor Team USA in Tokyo Olympics — Gilead loses again in PrEP patent fight — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Leadership

Discussion in 'Questcor' started by Anonymous, Jul 30, 2014 at 5:45 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Seriously, Acthar is done, completely totally. The collapse has begun and Malli leadership has no clue what to do with this drug.
     

  2. Anonymous

    Anonymous Guest

    Nephrology is dying a quick death. Look at the data! Joe is/will be the next one to go and take the heat for the failure to deliver. Wait and see.
     
  3. Anonymous

    Anonymous Guest

    No I was actually referring to the "GM" in Pulmonology. You know the one who was placed into that position with ZERO Pulmonology/Allergy AND sales experience!!!! This is why he is now GONE!
     
  4. Anonymous

    Anonymous Guest

    Here is a novel IDEA....! Why not hire someone with deep Nephrology experience to run the Nephrology business, and Pulmonology experience to run the PUD business, and MS experience....instead of promoting your "friends" to these positions!!
    You get the idea. Such a basic and fundamental business 101 principle that many people do not practice or understand. I once read a quote that read "We hire smart people to tell us what to do NOT so we can tell them what to do". Get it?

    I can't tell you how many times I have seen people promote their friends to leadership positions in this industry only to see if backfire like it did here. When will people learn!?!?
     
  5. Don't worry, Mallinckrodt knows just what to do to turn Acthar around. Fire internal people and talk really tough to the sales force. Yep, that should do it Hugh. It couldn't possibly be that you have already demoralized the team that built the damn drug. Doesn't matter anyway it is too late. Look out below.
     
  6. Anonymous

    Anonymous Guest

    Let's be honest the majority of the people who got fired needed to be fired. And the ones who they put in leadership positions before they were fired also need to be fired. The downward spiral started here about 18 months ago.
     
  7. Anonymous

    Anonymous Guest

    If you really want to get honest, might as well fire everyone and keep the 20 or so reps across the divisions that bring in almost 90% of the acthar revenue. I'm sure the books would look real good after you get rid of all the inflated salaries here. But that would never happen...would it ?
     
  8. Anonymous

    Anonymous Guest

    Mallinckrodt management is posting on here, obviously from the last two posts. You douches are killing Acthar and you don't have a clue what to do to fix it. The people that built the brand from nothing to $1B aren't the problem. It was growing up through the time the deal closed. From that point it has been in decline. You may not like to hear it, but the numbers don't lie.
     
  9. Anonymous

    Anonymous Guest

    You are all smoking some good stuff - this drug has been smoke and mirrors for years. With retro studies with N's of 6 and a bulging price, lack of true efficacy. The leadership did a ton of propping up to bloat their stock options year after year, staying one step ahead of the OIG - face it the run is over. Anyone that still hangs on and thinks there is a future is truly an idiot.
     
  10. Anonymous

    Anonymous Guest

    OMG shorty! is that you? Where you been?
     
  11. Anonymous

    Anonymous Guest

    Acthar price increase to $40,000 a vial.....HUB that functions worse than your local DMV....Payers on a "mission" to halt Acthar from being approved in 2015.....Quotas increasing.....no real clinical data......no academic center clout.....smaller territories.....deaf management.........yeah, MNK def knows what they are doing! NOT
     
  12. Anonymous

    Anonymous Guest

    THe only think that will save Acthar in meeting its goals is a price increase. You are all naive if you think this is a good place to make money and grow your career. The Acthar boat has left the dock about 18 months ago and will not be coming back. The decline/decrease in mkt share has already begun...


    Sales of Acthar, Questcor's long-running breadwinner, came in at $228 million for the quarter, just below Tsao's $230 million forecast. Tsao expects the drug to expand into markets including ophthalmology and pulmonology, but says that growth expectations should be reset to lower levels because the drug is now building upon so large a market base.
     
  13. Anonymous

    Anonymous Guest

    I agree...... I'd turn it over to my local DMV. I can get them on the phone, they answer my questions. I can walk in and get what I need during normal business hours. They give reliable information. They are better than our HUB in ever aspect come to think of it. RM's now have to use email and be happy with a 36 hour turnaround? Laughable!!!!!!!!!!
     
  14. Anonymous

    Anonymous Guest

    But what happened to all those big promises Todd Killian made to us at the NSM? I thought all would be well now that he had taken over reimbursement? On the contrary Todd, things have only gotten worse, much worse.
     
  15. Anonymous

    Anonymous Guest

    What you may not understand ( ai assuming you are not in sales here) is that the issues with reimbursement have little to do with the HUB or Todd. They have everything to do with payers refusing to reimburse Acthar for specific indications period.

    You can hire all of the people you want at the HUB to call, email, wirte, try to push the reimbursement through but if the payer will not reimburse it OR make it nearly and virtualy impossible to get reimbursed , which they are now doing, this is where the HUB issues are. unless there is legislation passed to mandate this drug be reimbursed by some of the countries largest payers you will continue to see a gradual decline that has been taking place for the last 18 months.

    In response the company will increase cost of the drug which in turns causes additional payers to put up the same road blocks for reimbursement and existing payers who were not paying put up MORE blocks. It's a game of cat and mouse the drug industry will never win once it gets to a certain point which Acthar is already in. As everyone was saying this drug is done without any really hard clinical data to support its utilization in existing disease states. This is not a good place to be financially or career wise.

    IMO Mallink SIGNIFICANTLY overpaid for this company by at least $1.5 billion. Cheap money help them justifying overpaying.
     
  16. Anonymous

    Anonymous Guest

    Good points... payers refusing to pay. Leadership lacking awareness of how difficult this product is to sell. HOWEVER, HUB sucks. We pay them and the enviornment feels like we work for them. Todd recognized no metrics or accountability. Months later, still no metrics or accountability. Communication between field and HUB needs to increase, not decrease. AMB's should have dedicated HUB Specialists (and I use the term Specialist very loosely). Price should be decreasing, not increasing. MS? NS? RA? NOT RARE DISEASES!!!! Contracts with rebates of 5-10% are laughable. PBM Directors are now pissed and looking to take agressive positions to block all Acthar. I'll give credit on the last post where due but you have much to learn about what it's like in the trenches.
     
  17. Anonymous

    Anonymous Guest

    agree. we are selling for acute flares in most cases. time is a critical issue to our customers and patients.
     
  18. Anonymous

    Anonymous Guest

    acute flares? haha.
     
  19. Anonymous

    Anonymous Guest

    If this guy isnt looking for a job he is out of his mind.
     
  20. Anonymous

    Anonymous Guest

    Wow..and the new concept of "Segmentation" is going to sell a ton of Acthar ,eliminate all the insurance denials and double sales...not! Big Pharma mentality..letting the tail wag the dog..